Sanofi reported strong growth in Q3 2024 with a 16% increase in CER for total sales of 13.4 billion euros. Dupixent and Vaccine business showed robust growth. Opella deal was discussed, with cash proceeds expected in Q2 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing